All In Biotech

Drug Trial Radar · NCT03971422

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

200

Actual

Start

Jun 3, 2019

Primary completion

Aug 31, 2021

Study completion Oct 26, 2021

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • RozanolixizumabDrug

    Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) ScoreTime frame: Baseline and Day 43

Locations

112 sites in 17 countries. Site status is shown where the registry gives one.

  • Mg0003 50081

    Phoenix, Arizona

  • Mg0003 50082

    Scottsdale, Arizona

  • Mg0003 50072

    Los Angeles, California

  • Mg0003 50092

    Orange, California

  • Mg0003 50097

    San Francisco, California

  • Mg0003 50099

    San Francisco, California

  • Mg0003 50101

    Aurora, Colorado

  • Mg0003 50088

    Washington D.C., District of Columbia

  • Mg0003 50122

    Miami, Florida

  • Mg0003 50120

    Miami, Florida

  • Mg0003 50073

    Tampa, Florida

  • Mg0003 50075

    Augusta, Georgia

  • Mg0003 50323

    Honolulu, Hawaii

  • Mg0003 50109

    Chicago, Illinois

  • Mg0003 50114

    Indianapolis, Indiana

  • Mg0003 50074

    Fairway, Kansas

  • Mg0003 50121

    Lexington, Kentucky

  • Mg0003 50110

    Ann Arbor, Michigan

  • Mg0003 50102

    Detroit, Michigan

  • Mg0003 50104

    Rochester, Minnesota

  • Mg0003 50105

    St Louis, Missouri

  • Mg0003 50077

    New York, New York

  • Mg0003 50117

    Charlotte, North Carolina

  • Mg0003 50086

    Charlotte, North Carolina

  • Mg0003 50090

    Winston-Salem, North Carolina

  • Mg0003 50076

    Columbus, Ohio

  • Mg0003 50096

    Philadelphia, Pennsylvania

  • Mg0003 50089

    Philadelphia, Pennsylvania

  • Mg0003 50084

    Charleston, South Carolina

  • Mg0003 50113

    Houston, Texas

  • Mg0003 40121

    Brussels, Belgium

  • Mg0003 50067

    Calgary, Canada

  • Mg0003 50066

    Montreal, Canada

  • Mg0003 50070

    Québec, Canada

  • Mg0003 50069

    Toronto, Canada

  • Mg0003 40125

    Ostrava, Czechia

  • Mg0003 40124

    Prague, Czechia

  • Mg0003 40128

    Aalborg, Denmark

  • Mg0003 40127

    Aarhus N, Denmark

  • Mg0003 40126

    Copenhagen, Denmark

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.